skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Adenocarcinoma of the lung: ten years' experience in Southern Alberta Cancer Center

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

During the period from 1968 to 1977, 1223 patients with carcinoma of the lung were registered at the Southern Alberta Cancer Center, of whom 121 (10%) had adenocarcinoma of the lung. A detailed retrospective analysis was undertaken to determine prognostic factors and the causes of treatment failure. The median age of the patients was 60 years. Curative surgical removal was accomplished in 63 patients; in 19 patients biopsy or palliative resection only was possible at the time of thoracotomy. Cobalt teletherapy was given to the primary site and mediastinum in 50 patients, with tumor doses ranging from 3000 rad in 2 weeks to 5000 rad in 5 weeks. Chemotherapy was given to 24 patients, either single agent or combination, using Cyclophosphamide, Vincristine, Methotrexate and 5 Fluoruracil. The 2 year actuarial survival rate was 59% for Stage 1 (standard error 0.13), 17% for Stage 2 (standard error 0.11) and 6% for Stage 111 (standard error 0.03). The important prognostic factors were stage of tumor, size of tumor, nodal status, presence of distant metastases, differentiation of tumor, involvement of the resection margin, performance status, and the level of hemoglobin at the time of diagnosis. Sex, age of the patient, and radiation dose did not affect the prognosis. Most of the recurrences and deaths occurred within 2 years of diagnosis (45/47). Among the 47 recurrences, 10 patients had only brain metastases with primary site control, 10 patients had a first recurrence in the primary site which had not been irradiated, 5 had a recurrence at a nonirradiated regional lymphatic site, 4 had a recurrence at the irradiated primary site, 8 had a recurrence at other sites, and 10 had multiple metastases at the time of treatment failure. The role of prophylactic brain radiation may have to be found with well controlled clinical trials.

Research Organization:
Southern Alberta Cancer Center, Calgary
OSTI ID:
6759182
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 6:7
Country of Publication:
United States
Language:
English

Similar Records

Radiation therapy for Ewing's sarcoma: Results from Memorial Sloan-Kettering in the modern era
Journal Article · Wed Feb 01 00:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:6759182

Predictors of Survival in Contemporary Practice After Initial Radiosurgery for Brain Metastases
Journal Article · Fri Mar 01 00:00:00 EST 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:6759182

Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma
Conference · Tue Jan 01 00:00:00 EST 1980 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6759182